Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Bakersfield › NPI 1720282585
Physician

Universal Healthcare Services INC.

Universal Healthcare Services INC. was paid $24.01M by Medicaid between Jan 2018 and Dec 2024, across 82 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 28% of everything it billed.

33Billing provider infoUNIVERSAL HEALTHCARE SERVICES INC.
BAKERSFIELD, CA 93312
33aNPI1720282585assigned 06/13/2007
28Total paid$24.01M
24GClaims330,114
24DCodes billed82
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Family Medicine Physician providers in California

Rank by total paid#20 of 2,511
Median peer was paid$13K
This provider vs. median1,869×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201829,276$2.07M
201941,398$2.97M
202049,516$3.58M
202152,917$4.09M
202250,376$3.58M
202357,977$3.64M
2024incomplete48,654$4.08M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 28% 112,161 109,746 $6.65M
27096 24% 17,937 10,320 $5.80M
64483 8.6% 13,050 7,667 $2.05M
64484 6.2% 8,576 4,480 $1.49M
76881 5.7% 18,579 18,268 $1.37M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 5.4% 25,212 25,152 $1.31M
76942 3.8% 17,852 17,526 $907K
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 3.6% 17,687 17,286 $857K
99152 2.8% 12,680 12,150 $681K
20610 1.9% 8,506 6,762 $459K
99245 1.5% 2,197 2,189 $353K
62321 1.1% 1,055 1,017 $265K
70 more codes
99204 Doctor's office visit, new patient (more involved) <1% 2,279 $224K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 1,743 $202K
20553 <1% 2,982 $196K
95886 <1% 1,039 $117K
95913 <1% 271 $102K
64493 <1% 710 $94K
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg <1% 18,296 $93K
96132 <1% 408 $68K
99244 Office or other outpatient consultation, moderate to high complexity <1% 476 $57K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 1,606 $53K
95912 <1% 154 $49K
64494 <1% 672 $47K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 3,889 $45K
J1030 Injection, methylprednisolone acetate, 40 mg <1% 4,925 $44K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 209 $41K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 6,750 $39K
0012A <1% 904 $35K
J3490 Unclassified drugs <1% 4,357 $31K
0011A <1% 906 $30K
96110 Developmental screening, with scoring and documentation, per standardized instrument <1% 480 $25K
96138 <1% 372 $19K
0001A <1% 474 $19K
0002A <1% 444 $18K
64635 <1% 86 $17K
92551 <1% 1,908 $15K
99203 Doctor's office visit, new patient (routine) <1% 306 $14K
95991 <1% 55 $14K
64495 <1% 145 $11K
20552 <1% 161 $9K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 297 $7K
0013A <1% 162 $6K
0031A <1% 156 $6K
95885 <1% 76 $6K
99392 Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) <1% 89 $6K
0072A <1% 136 $5K
S0020 Injection, bupivicaine hydrochloride, 30 ml <1% 1,133 $5K
99395 Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years <1% 102 $5K
81003 <1% 1,054 $4K
86328 <1% 132 $4K
0071A <1% 96 $4K
64636 <1% 62 $4K
99243 <1% 42 $4K
99393 Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) <1% 65 $4K
99394 Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) <1% 42 $3K
63650 <1% 24 $3K
99396 Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years <1% 42 $3K
99384 <1% 14 $2K
99173 <1% 1,045 $2K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 97 $2K
85018 <1% 471 $2K
90697 <1% 14 $1K
0003A <1% 27 $1K
L3908 Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf <1% 12 $517.88
92012 Ophthalmological services: medical examination and evaluation, intermediate, established patient <1% 101 $512.55
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 92 $506.68
G0283 Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care <1% 96 $483.36
90670 <1% 30 $465.13
G8731 Pain assessment using a standardized tool is documented as negative, no follow-up plan required <1% 5,594 $411.12
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward <1% 12 $391.86
G8730 Pain assessment documented as positive using a standardized tool and a follow-up plan is documented <1% 5,597 $275.99
83655 <1% 45 $265.63
87400 <1% 50 $145.34
90658 <1% 31 $120.38
99442 <1% 236 $66.59
96127 <1% 12 $48.10
J1330 Injection, ergonovine maleate, up to 0.2 mg <1% 179 $6.05
3074F 0% 34 $0.00
99422 0% 48 $0.00
G8539 Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment 0% 37 $0.00
3078F 0% 31 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPARMAR, ASHOK (PRESIDENT)
Same official

Other billing entities under PARMAR, ASHOK

Full network →

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.